Sign In
Buy CRBP
$7.38
-0.160 (-2.12%)
At Close: Jun 03, 2026
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab
08:00am, Wednesday, 25'th Jun 2025
NORWOOD, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on oncology and obesity, to
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium
04:05pm, Tuesday, 24'th Jun 2025
NORWOOD, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Off
Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?
03:42pm, Tuesday, 17'th Jun 2025
CRBP's pipeline shows promise, especially CRB-701 with early signals of benefit and tolerability, but all programs remain in early clinical stages. The company's financial position is stable for now,
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
12:15pm, Friday, 23'rd May 2025
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
08:00am, Thursday, 22'nd May 2025
NORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Offi
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
08:00am, Monday, 19'th May 2025
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rache
Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?
08:51am, Friday, 16'th May 2025
While CRBP's pipeline shows promise, the company's lack of marketed products remains a concern.
3 Unconventional Cannabis Stocks to Watch in 2025
09:15am, Tuesday, 29'th Apr 2025
Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.
Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High?
10:56am, Friday, 18'th Apr 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 764.2% in Corbus Pharmaceuticals (CRBP). While the effectiveness of this highly sought-after metric is question
NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfoli
After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)
10:35am, Thursday, 20'th Mar 2025
Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earni
After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)
10:35am, Wednesday, 19'th Mar 2025
Corbus Pharmaceuticals (CRBP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analyst
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know
01:14pm, Thursday, 13'th Mar 2025
Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NORWOOD, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) (“Corbus” or the “Company”), announced that data from its US and UK conducted first-in-hum
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
07:30am, Tuesday, 11'th Feb 2025
NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the abstract for its first-in-human dos
